Anbc, Inc.
Anbc, Inc.
Your view on SYUP
Overview
What the company does, where it operates, and who runs it.
About Anbc, Inc.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Wei Dong
- Headquarters
- No 2020 Huqingping Road, Shanghai, CN
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- CEO
- Wei Dong
- Headquarters
- No 2020 Huqingping Road, Shanghai, CN
Shanghai Yutong Pharma, Inc. engages in the development, manufacturing, and commercialization of traditional Chinese herbal medicines and biological pharmaceuticals in the People's Republic of China.
Its products primarily include Qilisheng a product formulated to be a general health enhancer by fortifying the immune system; Qi-ju-di-huang, an oral solution that protects the kidney and the liver; Qing-re-jie-du, an oral solution that reduces fever and relieves heat; Sheng-mai-yin, a solution that protects energy and enhances body fluids; Xiao-qing-long, an oral solution that relieves cough and dyspnea; Shen-bao, a syrup for the treatment of impotence and spermatorrhoea; Ban-xia, a syrup that relieves cough; and Gan-mao-zhi-ke, a syrup that relieves flu symptoms, cough, and nasal congestion.
It also offers Ban-lan-gen that relieves cold and flu symptoms; Gan-mao-qing-re that relieves minor body aches and pains, and reduces fever; Huang-dan-yin-chen used in the treatment for jaundice infection hepatitis; and Liu-shen-qu for treatment of vomitings and dysentery. It offers its products to distributors on a wholesale basis.
The company is based in Shanghai, China.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Anbc, Inc., and the rating behind it. SYUP last traded at $0.0002, 0.0× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Anbc, Inc.. Starting points for Anbc, Inc.: P/E 0.0, EPS $0.02, beta -6.57 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Anbc, Inc.. Anbc, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Anbc, Inc.. Trailing twelve-month EPS for Anbc, Inc. stands at $0.02. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Anbc, Inc.. Anbc, Inc. has reported as a listed company since 2009. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Anbc, Inc. valued side by side against its closest peers. Anbc, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Anbc, Inc., and how their positions are changing. At a $15,920 market value, institutional positions materially move Anbc, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Anbc, Inc. executives and directors. Shares of Anbc, Inc. have traded between $0.0001 and $0.0050 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Anbc, Inc.. Anbc, Inc. is a $15,920 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Anbc, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Anbc, Inc.. Coverage tracks Anbc, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.